Business

Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans

(TheNewswire) Toronto, Ontario – TheNewswire – November 29, 202...

articleVentripoint Diagnostics Ltd.November 29, 20214/company/ventripoint-diagnostics-ltd/news/ventripoint-applauds-the-us-government-for-establishing-an-additional-payment-to-doctors-for-analyzing-3d-heart-scans
Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans

About this update from Ventripoint Diagnostics Ltd.

[{"type":"text","content":"Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Toronto, Ontario – TheNewswire –\nNovember 29, 2021\n \n \n - Ventripoint Diagnostics Ltd.\n(\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"), (TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF) is pleased that the U.S. Department of Health and\nHuman Services (HHS) through CMS (Centers for Medicare & Medicaid\nServices) has approved a new compensation for doctors to analyze 3D\nechocardiograms.\n \n \n \n \n “3D echocardiograms are regarded as the future\ntechnique for heart analysis due to the speed of collecting a single\nholographic image of the whole heart and the extra fee for\ncardiologists for analyzing these scans should accelerate the adoption\nof 3D technology,” stated Dr. George Adams CEO of Ventripoint.\n“The unique ability of the VMS+ technology to analyze both 2D and 3D\nimage datasets for the whole heart makes for a bright future for the\nCompany.”\n \n \n \n \n At the recommendation of the AMA (American Medical\nAssociation), the CMS has finalized a CPT (Current Procedural\nTerminology) billing code (+93319) for 3D echocardiographic imaging\nand postprocessing during transesophageal or transthoracic\nechocardiography.  Effective January 1, 2022, the CPT billing code\ncan be used by doctors and hospitals to claim reimbursement from\npayers (Medicare, Medicaid, insurance companies, etc.).\n \n \n \n \n This is a significant development for 3D\nechocardiography, which has struggled to be adopted due to poor image\nquality and difficulty of analysis.  Our 3D echo VMS+ product has\nrecently been shown (\n \n \n \n \n https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250005/\n \n \n \n \n ) to yield excellent results in 75% of children for the most\ndifficult heart chamber, the right ventricle. The Company believes it\ncan accelerate the adoption of 3D echocardiography by improving the\nease and success rate of reading the exams and generating MRI-grade\nmeasurements for all 4 chambers of the heart.\n \n \n \n \n There will always be a need for VMS+3.0 to analyze 2D\nechocardiography exams for the 25% of patients who generate unreadable\nimages in 3D scans.  The VMS+ sy...

More updates from Ventripoint Diagnostics Ltd.